7 research outputs found
Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico
Background: An accurate estimate of the total number of cases and severity of illness of an emerging infectious disease is
required both to define the burden of the epidemic and to determine the severity of disease. When a novel pathogen first
appears, affected individuals with severe symptoms are more likely to be diagnosed. Accordingly, the total number of cases
will be underestimated and disease severity overestimated. This problem is manifest in the current epidemic of novel
influenza A/H1N1.
Methods and Results: We used a simple approach to leverage measures of incident influenza A/H1N1 among a relatively
small and well observed group of US, UK, Spanish and Canadian travelers who had visited Mexico to estimate the incidence
among a much larger and less well surveyed population of Mexican residents. We estimate that a minimum of 113,000 to
375,000 cases of novel influenza A/H1N1 have occurred in Mexicans during the month of April, 2009. Such an estimate
serves as a lower bound because it does not account for underreporting of cases in travelers or for nonrandom mixing
between Mexican residents and visitors, which together could increase the estimates by more than an order of magnitude.
Conclusions: We find that the number of cases in Mexican residents may exceed the number of confirmed cases by two to
three orders of magnitude. While the extent of disease spread is greater than previously appreciated, our estimate suggests
that severe disease is uncommon since the total number of cases is likely to be much larger than those of confirmed cases
Household Responses to School Closure Resulting from Outbreak of Influenza B, North Carolina
Parents accepted school closure during an outbreak, but children’s presence in other public settings has implications for pandemic planning
Cases of novel influenza A/H1N1 among travelers to Mexico from three countries as of May 6, 2009 (Canada) or May 8, 2009 (US, UK, Spain) and associated estimates.
<p>Cases of novel influenza A/H1N1 among travelers to Mexico from three countries as of May 6, 2009 (Canada) or May 8, 2009 (US, UK, Spain) and associated estimates.</p
Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial.
BACKGROUND: Corticosteroids have been used to treat head injuries for more than 30 years. In 1997, findings of a systematic review suggested that these drugs reduce risk of death by 1-2%. The CRASH trial--a multicentre international collaboration--aimed to confirm or refute such an effect by recruiting 20000 patients. In May, 2004, the data monitoring committee disclosed the unmasked results to the steering committee, which stopped recruitment. METHODS: 10008 adults with head injury and a Glasgow coma score (GCS) of 14 or less within 8 h of injury were randomly allocated 48 h infusion of corticosteroids (methylprednisolone) or placebo. Primary outcomes were death within 2 weeks of injury and death or disability at 6 months. Prespecified subgroup analyses were based on injury severity (GCS) at randomisation and on time from injury to randomisation. Analysis was by intention to treat. Effects on outcomes within 2 weeks of randomisation are presented in this report. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN74459797. FINDINGS: Compared with placebo, the risk of death from all causes within 2 weeks was higher in the group allocated corticosteroids (1052 [21.1%] vs 893 [17.9%] deaths; relative risk 1.18 [95% CI 1.09-1.27]; p=0.0001). The relative increase in deaths due to corticosteroids did not differ by injury severity (p=0.22) or time since injury (p=0.05). INTERPRETATION: Our results show there is no reduction in mortality with methylprednisolone in the 2 weeks after head injury. The cause of the rise in risk of death within 2 weeks is unclear